ライフサイエンスコーパス: mesna

1 upratherapeutic concentrations of dimesna or mesna.

2 ophenol/benzyl mercaptan, or the alkanethiol MESNA.

3 Mesna: (1) Mesna, dosed as detailed in these guidelines,

4 cinoma were treated with IFX 3,750 mg/m2 and mesna 2250 mg/m2 both intravenously (IV) daily for 2 day

5 of ICE on days 1-3 (ifosfamide 5 g/m(2) plus mesna 5 g/m(2) intravenously over 24 h on day 2, carbopl

6 /m(2) over 3 h on days 10, 12, and 14), plus mesna (500 mg/m(2) at 0, 3, 7 and 11 h), and bleomycin (

7 ifosfamide 5000 mg/m(2) in combination with mesna 5000 mg/m(2) continuous infusion over 24 h, days 1

8 IFX) 5 g/m2 given as a 24-hour infusion plus mesna 6 g/m2 during and for 12 hours after the ifosfamid

9 )), ifosfamide (5 g/m(2) over 24 hours), and mesna (6 g/m(2) during ifosfamide infusion and the follo

10 )), ifosfamide (5 g/m(2) over 24 hours), and mesna (6 g/m(2) during ifosfamide infusion and the follo

11 Mesna, 600 mg/m2 every 6 hours, was given until 24 hours

12 a dose change of IFX to 1,500 mg/m2 IV with mesna 750 mg/m2 IV for 5 days every 3 weeks.

13 Mesna and dimesna concentrations were measured by specif

14 closely matched the summed concentration of mesna and dimesna emerging in the effluent perfusate (si

15 The urinary profiles of mesna and dimesna excretion were determined on days 1, 2

16 s to reinvestigate the hepatic metabolism of mesna and dimesna.

17 HDI at 14 g/m2 with mesna and G-CSF is an active salvage regimen for patient

18 administered by a bolus schedule, along with mesna and G-CSF.

19 ous intravenous infusion (in 22 cases), with mesna and hydration.

20 (30 mg/kg; 1 gm maximum) accompanied by I.V. mesna and large amounts of I.V. fluids.

21 plus ifosfamide (10 g/m(2) over 4 days with mesna and pegfilgrastim) as first-line treatment.

22 m(2) per dose intravenously on days 1-3 with mesna) and doxorubicin (37.5 mg/m(2) per dose intravenou

23 ctice guidelines for the use of dexrazoxane, mesna, and amifostine in patients who are not enrolled o

24 adiotherapy-protectant activity-dexrazoxane, mesna, and amifostine-and questions about the role of th

25 data regarding the activity of dexrazoxane, mesna, and amifostine.

26 antation or up to four cycles of ifosfamide, mesna, and etoposide alternating with DECAL maintenance

27 phamide (65 mg/kg/d x 2 days per cycle) with mesna, and methotrexate (400 mg/kg per cycle) with leuco

28 The effluent mesna concentration correlated inversely with the flow r

29 The investigational regimen included an I.V. mesna dose given concurrently with ifosfamide, followed

30 Mesna: (1) Mesna, dosed as detailed in these guidelines, is recomme

31 I.V. and oral mesna doses equaled 20% and 40%, respectively, of the if

32 es of neoadjuvant chemotherapy (CT; modified mesna, doxorubicin, ifosfamide, and dacarbazine [MAID]),

33 -CSF 10 micrograms/kg/d on days 2 to 12, and mesna, every 2 weeks for eight cycles.

34 ter ifosfamide administration, the amount of mesna excreted and the profile of urinary mesna excretio

35 hours 0 through 12 and the sustained urinary mesna excretion during hours 12 through 24.

36 of mesna excreted and the profile of urinary mesna excretion was similar for both regimens; however,

37 pounds, THIP hydrochloride, methenamine, and mesna, have shown promise as novel gut microbiome therap

38 on may counterbalance the rapid oxidation of mesna in plasma.

39 ation of the perfusate in the reservoir, but mesna injected directly into the perfusate just before e

40 Mesna is administered with ifosfamide and cyclophosphami

41 t model of mesna metabolism and disposition, mesna is rapidly and irreversibly oxidized to dimesna in

42 In the present model of mesna metabolism and disposition, mesna is rapidly and i

43 al observations and suggests a new model for mesna metabolism and disposition.

44 ch; amifostine, 33 reports (31 studies); and mesna, no published randomized trials identified since 2

45 during recirculation of perfusates with 1 mM mesna or 250 microM dimesna.

46 (3) Either mesna or forced saline diuresis is recommended to decrea

47 hosphamide superior to the standard of care, mesna or nicotinamide-induced DNA demethylation.

48 ized to receive either the I.V.-oral or I.V. mesna regimen on day 1, followed by crossover to the oth

49 uld be at least as uroprotective as the I.V. mesna regimen.

50 struct 1 with 2-mercaptoethanesulfonic acid (MESNA) resulted in the MESNA thioester of R2 (1-353) (co

51 yl) and tris(carboxamidomethyl) catalyzed by MESNa (sodium 2-mercaptoethylsulphonate) or MPAA (4-merc

52 1000 mL in a 24 h intravenous infusion with mesna support, day 2; carboplatin area under the curve o

53 and 8 hours later by oral administration of mesna tablets.

54 oethanesulfonic acid (MESNA) resulted in the MESNA thioester of R2 (1-353) (construct 2).

55 Our detection of a high ratio of mesna to dimesna in the plasma of clinical samples led u

56 on which to base a guideline for the use of mesna to prevent urothelial toxicity with ifosfamide dos

57 isted of two cycles of ICE chemotherapy with mesna uroprotection and aHPCS.

58 g/m(2)) at 2.8 g/m(2) per day with equidose mesna uroprotection, followed by etoposide 100 mg/m(2) p

59 Mesna was administered similarly (both arms); filgrastim

60 During hours 12 to 24, about eightfold more mesna was excreted by patients given the I.V.-oral than

61 Mesna was oxidized to dimesna during oxygenation of the

62 recurrence was prevented with i.v. and oral mesna, which permitted continued outpatient delivery.